vs
AdvanSix Inc.（ASIX）与IDEAYA Biosciences, Inc.（IDYA）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是IDEAYA Biosciences, Inc.的1.7倍（$359.9M vs $207.8M），IDEAYA Biosciences, Inc.净利率更高（57.4% vs -0.8%，领先58.2%），IDEAYA Biosciences, Inc.自由现金流更多（$142.2M vs $36.1M）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
IDEAYA Biosciences是一家临床阶段生物技术企业，专注于肿瘤学领域，研发针对基因定义癌症的靶向疗法及合成致死治疗方案，推进多肿瘤类型的候选药物管线开发，与行业伙伴合作提升全球创新癌症治疗方案的可及性。
ASIX vs IDYA — 直观对比
营收规模更大
ASIX
是对方的1.7倍
$207.8M
净利率更高
IDYA
高出58.2%
-0.8%
自由现金流更多
IDYA
多$106.0M
$36.1M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $207.8M |
| 净利润 | $-2.8M | $119.2M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | 52.2% |
| 净利率 | -0.8% | 57.4% |
| 营收同比 | 9.4% | — |
| 净利润同比 | -892.9% | 330.1% |
| 每股收益（稀释后） | $-0.11 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXIDYA
| Q4 25 | $359.9M | — | ||
| Q3 25 | $374.5M | $207.8M | ||
| Q2 25 | $410.0M | — | ||
| Q1 25 | $377.8M | — | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $0 | ||
| Q2 24 | $453.5M | $0 | ||
| Q1 24 | $336.8M | $0 |
净利润ASIXIDYA
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $119.2M | ||
| Q2 25 | $31.4M | — | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-51.8M | ||
| Q2 24 | $38.9M | $-52.8M | ||
| Q1 24 | $-17.4M | $-39.6M |
毛利率ASIXIDYA
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
营业利润率ASIXIDYA
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.9% | 52.2% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | 11.5% | — | ||
| Q1 24 | -7.0% | — |
净利率ASIXIDYA
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | 57.4% | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 6.2% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | -5.2% | — |
每股收益（稀释后）ASIXIDYA
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | $1.33 | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | $-0.60 | ||
| Q2 24 | $1.43 | $-0.68 | ||
| Q1 24 | $-0.65 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $786.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $1.1B |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXIDYA
| Q4 25 | $19.8M | — | ||
| Q3 25 | $23.7M | $786.9M | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $8.3M | — | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $920.0M | ||
| Q2 24 | $12.1M | $701.7M | ||
| Q1 24 | $20.6M | $698.8M |
股东权益ASIXIDYA
| Q4 25 | $815.2M | — | ||
| Q3 25 | $818.2M | $1.1B | ||
| Q2 25 | $823.7M | — | ||
| Q1 25 | $794.4M | — | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $1.2B | ||
| Q2 24 | $746.6M | $931.7M | ||
| Q1 24 | $713.2M | $935.3M |
总资产ASIXIDYA
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $973.7M | ||
| Q1 24 | $1.5B | $961.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $142.2M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $142.2M |
| 自由现金流率自由现金流/营收 | 10.0% | 68.4% |
| 资本支出强度资本支出/营收 | 7.7% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $6.4M | $13.5M |
8季度趋势，按日历期对齐
经营现金流ASIXIDYA
| Q4 25 | $63.7M | — | ||
| Q3 25 | $26.6M | $142.2M | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $-49.2M | ||
| Q2 24 | $50.2M | $-32.9M | ||
| Q1 24 | $-36.2M | $-43.8M |
自由现金流ASIXIDYA
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | $142.2M | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $-49.7M | ||
| Q2 24 | $16.7M | $-33.9M | ||
| Q1 24 | $-71.6M | $-45.1M |
自由现金流率ASIXIDYA
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | 68.4% | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
资本支出强度ASIXIDYA
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | 10.5% | — |
现金转化率ASIXIDYA
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
IDYA
暂无分部数据
